Julian Harrison, an analyst from BTIG, maintained the Buy rating on Connect Biopharma Holdings. The associated price target remains the same with $10.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Julian Harrison has given his Buy rating due to a combination of factors, notably the compelling Phase 1 data showing that IV rademikibart delivers very rapid and clinically meaningful lung function gains in both asthma and COPD, with FEV1 improvements that materially exceed those seen with standard inhaled and oral therapies. He sees particular upside in COPD, where current biologics and small molecules are positioned mainly for chronic maintenance and carry restrictions around acute use, creating a clear niche for an IV option in the hospital that could later transition patients onto a subcutaneous regimen for long-term control.
He also highlights supportive longer-term evidence from the Phase 3 RADIANT-AD trial in atopic dermatitis, where rademikibart achieved strong maintenance efficacy with favorable tolerability, reinforcing the drug’s broader commercial optionality, including potential ex-China partnering backed by milestone and royalty streams from Simcere. Combined with the recent $20.2M financing that extends CNTB’s cash runway into the second half of 2027 and the prospect of value-creating catalysts from the ongoing Seabreeze STAT studies and future Phase 3 planning, Harrison concludes that the risk/reward profile justifies a Buy recommendation on the shares.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $7.00 price target.